Is Sarepta Therapeutics, Inc. (SRPT) a Buy, Sell, or Hold?
Sarepta Therapeutics, Inc.
NASDAQ:SRPT
$17.61 USD
-$0.35 (-1.95%)
- Volume
- 3.46M
- Average Volume
- 3.29M
- Market Capitalization
- $1.86B
- P/E Ratio
- 28.40
- Dividend Yield
- 0.00%
- Price Target
- $25.00
- Year High
- $25.32
- Year Low
- $10.42
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.63
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Douglas S. Ingram |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | SRPT |
| CUSIP | 803607100 |
| CIK | 0000873303 |
| Web | https://www.sarepta.com |
| Phone | 617 274 4000 |
| Currency | USD |
| Employees | 835 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.69 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.63 |
| Quick Ratio | 2.62 |
| Cash Ratio | 0.93 |
Sales & Book Value
| Annual Sales | $2.2B |
| Price / Sales | 0.85 |
| Cash Flow | 1.01 |
| Price / Cash Flow | 17.52 |
| Price / Book | 1.23 |
Price Target and Rating
| Average Stock Price Forecast | $25.00 |
| High Stock Price Forecast | $35.00 |
| Low Stock Price Forecast | $14.00 |
| Forecast Upside/Downside | -29.56% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 55 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-7.13 |
| Trailing P/E Ratio | 28.40 |
| PEG Ratio | 0.06 |
| P/E Growth | 0.06 |
| Net Income | $-713.41M |
| Net Margin | 2.98% |
| Pretax Margin | 1.12% |
| Return on Equity | 4.89% |
| Return on Assets | 2.05% |
Financials Score
| AltmanZ Score | 0.13 |
| Piotroski Score | 8.00 |
| Working Capital | 1.81B |
| Total Assets | 3.18B |
| Ebit | 79.82M |
| Market Cap | 1.9B |
| Total Liabilities | 1.67B |
Poll Results
About Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stock
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and ... SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
2026-07-13 09:46:00
SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) against certain of its officers and directors for alleged breaches of fiduciary duty.
2 Beaten-Down Stocks That Still Aren't Worth Buying
2026-07-11 16:30:00
Recursion Pharmaceuticals has yet to prove that its approach to developing medicines is superior. Sarepta Therapeutics will struggle to shake off safety concerns about its most important therapy.
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout
2026-07-10 12:04:38
Biotech is the story at midday Friday, and it's not a pretty one for shareholders who chased the sector's monster 2026 run.
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-30 16:25:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 30 individuals hired by Sarepta in the second quarter of 2026. The equity awards were approved in accordance with Nasdaq Listing Rule.
Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs
2026-06-30 12:44:41
The U.S. Food and Drug Administration (FDA) accepted on Tuesday Sarepta Therapeutics Inc.'s (NASDAQ:SRPT) supplemental New Drug Applications seeking to convert the accelerated approvals of AMONDYS 45 (casimersen) and VYONDYS 53 (golodirsen) into traditional approvals for Duchenne muscular dystrophy (DMD).
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
2026-06-30 09:00:00
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administratio
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
2026-06-30 08:30:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Applications (sNDAs) for AMONDYS 45® (casimersen) and VYONDYS 53® (golodirsen) for the treatment of Duchenne muscular dystrophy (DMD). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action data of February 28, 2027. The sNDA.
SRPT or PRTA: Which Is the Better Value Stock Right Now?
2026-06-24 12:41:05
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Sarepta Therapeutics (SRPT) and Prothena (PRTA). But which of these two stocks is more attractive to value investors?
Frequently Asked Questions
-
What is the current Sarepta Therapeutics, Inc. (SRPT) stock price?
-
Sarepta Therapeutics, Inc.(NASDAQ:SRPT) stock price is $17.61 in the last trading session. During the trading session, SRPT stock reached the peak price of $25.32 while $10.42 was the lowest point it dropped to. The percentage change in SRPT stock occurred in the recent session was --1.95% while the dollar amount for the price change in SRPT stock was -$-0.35.
-
SRPT's industry and sector of operation?
-
The NASDAQ listed SRPT is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of SRPT?
-
Rachael Potter | Chief Scientific Officer
Diane L. Berry | Executive Vice President and Chief of Global Policy & Advocacy Officer
Tamara Thornton | Director of Finance, Treasury & Investor Relations
Ian Michael Estepan | President & Chief Operating Officer
Alison Nasisi | Executive Vice President & Chief People Officer -
How many employees does SRPT have?
-
Number of SRPT employees currently stands at 835. SRPT operates from 215 First Street, Cambridge, MA 02142, US.
-
Link for SRPT official website?
-
Official Website of SRPT is: https://www.sarepta.com
-
How do I contact SRPT?
-
SRPT could be contacted at phone #617 274 4000 and can also be accessed through its website. SRPT operates from 215 First Street, Cambridge, MA 02142, US.
-
How many shares of SRPT are traded daily?
-
The average number of SRPT shares traded daily for last 3 months was 3.29M.
-
What is the market cap of SRPT currently?
-
The market value of SRPT currently stands at $1.86B with its latest stock price at $17.61